Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1966 1
1968 2
1969 1
1970 1
1972 1
1973 1
1974 1
1977 1
1978 2
1980 2
1981 2
1983 1
1985 1
1986 1
1987 1
1988 2
1990 4
1991 3
1992 1
1993 4
1994 7
1995 4
1996 3
1997 4
1998 2
1999 3
2000 2
2001 2
2002 4
2003 2
2004 2
2005 2
2006 2
2007 4
2008 6
2009 6
2010 7
2011 6
2012 9
2013 6
2014 10
2015 18
2016 15
2017 24
2018 22
2019 15
2020 20
2021 15
2022 5
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

225 results

Results by year

Filters applied: . Clear all
Page 1
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Dreyling M, Ghielmini M, Rule S, Salles G, Ladetto M, Tonino SH, Herfarth K, Seymour JF, Jerkeman M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Dreyling M, et al. Among authors: rule s. Ann Oncol. 2021 Mar;32(3):298-308. doi: 10.1016/j.annonc.2020.11.008. Epub 2020 Nov 26. Ann Oncol. 2021. PMID: 33249059 Free article. No abstract available.
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. Younes A, et al. Among authors: rule s. Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. Ann Oncol. 2017. PMID: 28379322 Free PMC article. Review.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W. Wang M, et al. Among authors: rule s. Lancet. 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11. Lancet. 2018. PMID: 29241979 Free PMC article. Clinical Trial.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Wang ML, et al. Among authors: rule s. N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19. N Engl J Med. 2013. PMID: 23782157 Free PMC article. Clinical Trial.
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
Le Gouill S, Morschhauser F, Chiron D, Bouabdallah K, Cartron G, Casasnovas O, Bodet-Milin C, Ragot S, Bossard C, Nadal N, Herbaux C, Tessoulin B, Tchernonog E, Rossi C, McCulloch R, Gastinne T, Callanan MB, Rule S. Le Gouill S, et al. Among authors: rule s. Blood. 2021 Feb 18;137(7):877-887. doi: 10.1182/blood.2020008727. Blood. 2021. PMID: 33181832 Free article. Clinical Trial.
Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology.
Jones GL, Will A, Jackson GH, Webb NJ, Rule S; British Committee for Standards in Haematology. Jones GL, et al. Among authors: rule s. Br J Haematol. 2015 Jun;169(5):661-71. doi: 10.1111/bjh.13403. Epub 2015 Apr 15. Br J Haematol. 2015. PMID: 25876990 Free article. No abstract available.
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. Dreyling M, et al. Among authors: rule s. Lancet. 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7. Lancet. 2016. PMID: 26673811 Clinical Trial.
Novel agents in mantle cell lymphoma.
Tucker D, Rule S. Tucker D, et al. Among authors: rule s. Expert Rev Anticancer Ther. 2017 Jun;17(6):491-506. doi: 10.1080/14737140.2017.1328280. Epub 2017 May 17. Expert Rev Anticancer Ther. 2017. PMID: 28480764 Review.
225 results